Oral Peptide Nano-Formulations for Breast Cancer: An Enhancer-Centric, Regulatory-Ready Path to Clinical Translation

Area of Science:

• Oncology
• Pharmaceutical Sciences
• Drug Delivery

Background:

• Breast cancer management increasingly requires long-term, tolerable therapies.
• Peptide therapeutics offer specificity but are limited by parenteral delivery.
• Oral delivery of peptides faces significant gastrointestinal barriers, including degradation and poor absorption.

Purpose of the Study:

• To evaluate oral peptide nano-formulations with permeation enhancers for breast cancer treatment.
• To assess the potential for clinically meaningful oral absorption of peptide drugs.
• To adopt a translational, industry-oriented perspective focusing on regulatory alignment and chronic-use safety.

Main Methods:

• Critical review of oral peptide nano-formulations incorporating molecular permeation enhancers.
• Examination of enhancer classes: medium-chain fatty acids, bile-derived agents, and surfactant-based enhancers.
• Analysis of mechanistic and translational aspects, including epithelial reversibility and tolerability.

Main Results:

• Permeation enhancers can facilitate clinically meaningful oral absorption of peptide drugs.
• An enhancer-centric paradigm protects peptides and localizes exposure at the absorption site.
• Key enhancer classes demonstrate potential for improving oral peptide bioavailability.

Conclusions:

• Oral peptide nano-formulations with permeation enhancers represent a pragmatic approach for chronic breast cancer therapy.
• Focus on regulatory alignment, safety, manufacturability, and CMC robustness is crucial for clinical translation.
• This strategy enhances patient adherence, quality of life, and healthcare efficiency.